Literature DB >> 29433793

Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases.

Maite Calucho1, Sara Bernal2, Laura Alías3, Francesca March2, Adoración Venceslá4, Francisco J Rodríguez-Álvarez5, Elena Aller6, Raquel M Fernández7, Salud Borrego8, José M Millán9, Concepción Hernández-Chico10, Ivon Cuscó11, Pablo Fuentes-Prior12, Eduardo F Tizzano13.   

Abstract

Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss or mutations in SMN1. According to age of onset, achieved motor abilities, and life span, SMA patients are classified into type I (never sit), II (never walk unaided) or III (achieve independent walking abilities). SMN2, the highly homologous copy of SMN1, is considered the most important phenotypic modifier of the disease. Determination of SMN2 copy number is essential to establish careful genotype-phenotype correlations, predict disease evolution, and to stratify patients for clinical trials. We have determined SMN2 copy numbers in 625 unrelated Spanish SMA patients with loss or mutation of both copies of SMN1 and a clear assignation of the SMA type by clinical criteria. Furthermore, we compiled data from relevant worldwide reports that link SMN2 copy number with SMA severity published from 1999 to date (2834 patients with different ethnic and geographic backgrounds). Altogether, we have assembled a database with a total of 3459 patients to delineate more universal prognostic rules regarding the influence of SMN2 copy number on SMA phenotype. This issue is crucial in the present scenario of therapeutic advances with the perspective of SMA neonatal screening and early diagnosis to initiate treatments.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Phenotype–genotype correlations; Prognosis considerations; SMN2 copies; Spinal muscular atrophy; Worldwide compilation

Mesh:

Substances:

Year:  2018        PMID: 29433793     DOI: 10.1016/j.nmd.2018.01.003

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  58 in total

Review 1.  Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.

Authors:  Giuseppe Vita; Gian Luca Vita; Olimpia Musumeci; Carmelo Rodolico; Sonia Messina
Journal:  Neurol Sci       Date:  2019-02-25       Impact factor: 3.307

2.  Novel PGD strategy based on single sperm linkage analysis for carriers of single gene pathogenic variant and chromosome reciprocal translocation.

Authors:  Yuqian Wang; Xiaohui Zhu; Zhiqiang Yan; Xu Zhi; Shuo Guan; Ying Kuo; Yanli Nie; Ying Lian; Jin Huang; Yuan Wei; Ping Liu; Rong Li; Jie Qiao; Liying Yan
Journal:  J Assist Reprod Genet       Date:  2020-04-29       Impact factor: 3.412

3.  Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype.

Authors:  Corey Ruhno; Vicki L McGovern; Matthew R Avenarius; Pamela J Snyder; Thomas W Prior; Flavia C Nery; Abdurrahman Muhtaseb; Jennifer S Roggenbuck; John T Kissel; Valeria A Sansone; Jennifer J Siranosian; Alec J Johnstone; Pann H Nwe; Ren Z Zhang; Kathryn J Swoboda; Arthur H M Burghes
Journal:  Hum Genet       Date:  2019-02-20       Impact factor: 4.132

Review 4.  Spinal muscular atrophy - insights and challenges in the treatment era.

Authors:  Eugenio Mercuri; Maria Carmela Pera; Mariacristina Scoto; Richard Finkel; Francesco Muntoni
Journal:  Nat Rev Neurol       Date:  2020-10-14       Impact factor: 42.937

5.  Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling.

Authors:  Laura Alías; Sara Bernal; Maite Calucho; Elisabeth Martínez; Francesca March; Pia Gallano; Pablo Fuentes-Prior; Anna Abuli; Clara Serra-Juhe; Eduardo F Tizzano
Journal:  Eur J Hum Genet       Date:  2018-06-14       Impact factor: 4.246

Review 6.  Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.

Authors:  Flavien Bizot; Adeline Vulin; Aurélie Goyenvalle
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

Review 7.  Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies.

Authors:  Raffaella Adami; Daniele Bottai
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 5.739

Review 8.  Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges.

Authors:  Annarita Miccio; Panagiotis Antoniou; Sorana Ciura; Edor Kabashi
Journal:  Mol Ther       Date:  2021-04-03       Impact factor: 11.454

9.  Comprehensive Mutation Analysis and Report of 12 Novel Mutations in a Cohort of Patients with Spinal Muscular Atrophy in Iran.

Authors:  Zohreh Sharifi; Mohammad Taheri; Mohammad-Sadegh Fallah; Maryam Abiri; Fatemeh Golnabi; Hamideh Bagherian; Razieh Zeinali; Hossein Farahzadi; Marjan Alborji; Pardis Ghazizadeh Tehrani; Masoume Amini; Sadaf Asnavandi; Mehrdad Hashemi; Flora Forouzesh; Sirous Zeinali
Journal:  J Mol Neurosci       Date:  2021-01-22       Impact factor: 3.444

10.  Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.

Authors:  Laura Bianchi; Maria Sframeli; Lorenza Vantaggiato; Gian Luca Vita; Annamaria Ciranni; Francesca Polito; Rosaria Oteri; Eloisa Gitto; Fabrizio Di Giuseppe; Stefania Angelucci; Antonio Versaci; Sonia Messina; Giuseppe Vita; Luca Bini; M'hammed Aguennouz
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.